title: Recombinant allergens: the present and the future.
abstract: Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.
authors.affiliation: Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland. marek.jutel@am.wroc.pl
authors.forename: Marek
authors.initials: M
authors.lastname: Jutel
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Solarewicz-Madejek
authors.forename: Sylwia
authors.initials: S
authors.lastname: Smolinska
mesh_terms: D000485:Allergens / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000485:Allergens; D014612:Vaccines
keywords: allergen-specific immunotherapy; allergy; hypoallergens; recombinant allergens; vaccines